Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge in the District of Columbia yesterday.
The court should reject UT’s challenge to the U.S. Health Resources and Services Administration’s (HRSA) May 17 letter informing UT that its actions resulted in overcharges and violated the 340B statute, the U.S. Justice Department (DOJ) said in an Aug. 10 filing in UT’s lawsuit against HRSA and the U.S. Health and Human Services Department (HHS).
Federal officials relied “on sound statutory interpretation and sufficient evidence” when it concluded in May that United Therapeutics (UT) broke the law when it conditioned access to 340B pricing on its products, government lawyers told a federal district judge in the District of Columbia yesterday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.